Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
07:21
George Simion, about the suspension of President Dan: "We already have a significant number of signatures. We will create a platform where every Romanian will be able to see if their parliamentarian has signed for the suspension or not."
07:04
George Simion, the leader of AUR, about the ANI law: "We will have another method through which Dominic Fritz will leave the mayor's chair of Timișoara"
23:12
Houthi militias in Yemen attacked two Saudi oil tankers, Wafa and Daisy, in the Red Sea and the Gulf of Aden
22:55
The British Foreign Secretary avoids answering whether he still considers Donald Trump an "idiot," "racist," and "misogynist."
22:41
Armed attack with multiple victims in Prospect Hill, North Carolina
See more news